30
| 1 | 2012
Klinisk Biokemi i Norden
(
Fortsat fra side 27)
11.
Narayan H, Dhillon OS, Quinn PA, Struck
J, Squire IB et al. C-terminal provasopres-
sin (copeptin) as a prognostic marker after
acute non-ST elevation myocardial infarc-
tion: Leicester Acute Myocardial Infarction
Peptide II (LAMP II) study. Clin Sci (Lond)
2011;121:79-89.
12.
Reichlin T, Hochholzer W, Stelzig C, Laule K,
Freidank H et al. Incremental value of copeptin
for rapid rule out of acute myocardial infarc-
tion. J Am Coll Cardiol 2009;54:60-8.
13.
Keller T, Tzikas S, Zeller T, Czyz E, Lillpopp
L et al. Copeptin improves early diagnosis of
acute myocardial infarction. J Am Coll Cardiol
2010;55:2096-106.
14.
Steen H, Giannitsis E, Futterer S, Merten C,
Juenger C, Katus HA. Cardiac troponin T at
96
hours after acute myocardial infarction cor-
relates with infarct size and cardiac function. J
Am Coll Cardiol 2006;48:2192-4.
15.
Giannitsis E, Kehayova T, Vafaie M, Katus HA.
Combined testing of high-sensitivity troponin
T and copeptin on presentation at prespecified
cutoffs improves rapid rule-out of non-ST-
segment elevation myocardial infarction. Clin
Chem 2011;57:1-4
16.
Meune C, Zuily S, Wahbi K, Claessens YE,
Weber S, Chenevier-Gobeaux C. Combina-
tion of copeptin and high-sensitivity cardiac
troponin T assay in unstable angina and non-
ST-segment elevation myocardial infarction: a
pilot study. Arch Cardiovasc Dis 2011;104:4-10.
17.
Karakas M, Januzzi JL Jr, Meyer J, Lee H,
Schlett CL et al. Bamberg F, Dasdemir S,
Hoffmann U, Koenig W. Copeptin does not
add diagnostic information to high-sensiti-
vity troponin T in low- to intermediate-risk
patients with acute chest pain: results from the
rule out myocardial infarction by computed
tomography (ROMICAT) study. Clin Chem
2011;57:1137-45.
18.
Bhandari SS, Loke I, Davies JE, Squire IB,
Struck J, Ng LL. Gender and renal function
influence plasma levels of copeptin in healthy
individuals. Clin Sci (Lond) 2009;116:257-63.
19.
Alehagen U, Dahlström U, Rehfeld JF, Goetze
JP. Association of copeptin and N-terminal
proBNP concentrations with risk of cardiovas-
cular death in older patients with symptoms of
heart failure. JAMA 2011;305:2088-95.
20.
Voors AA, von Haehling S, Anker SD, Hil-
lege HL, Struck J et al. OPTIMAAL Investi-
gators. C-terminal provasopressin (copeptin)
is a strong prognostic marker in patients with
heart failure after an acute myocardial infarc-
tion: results from the OPTIMAAL study. Eur
Heart J 2009;30:1187-94.
21.
Neuhold S, Huelsmann M, Strunk G, Struck J,
Adlbrecht C, Gouya G, Elhenicky M, Pacher R.
Prognostic value of emerging neurohormones
in chronic heart failure during optimization
of heart failure-specific therapy. Clin Chem
2010;56:121-6.
22.
Neuhold S, Huelsmann M, Strunk G, Stoiser
B, Struck J, Morgenthaler NG, Bergmann A,
Moertl D, Berger R, Pacher R. Comparison
of copeptin, B-type natriuretic peptide, and
amino-terminal pro-B-type natriuretic pep-
tide in patients with chronic heart failure:
prediction of death at different stages of the
disease. J Am Coll Cardiol 2008;52:266-72.
23.
Ambrosy A, Goldsmith SR, Gheorghiade M.
Tolvaptan for the treatment of heart failure: a
review of the literature. Expert Opin Pharma-
cother 2011;12:961-76.
24.
Morgenthaler NG, Müller B, Struck J, Berg-
mann A, Redl H, Christ-Crain M. Copeptin, a
stable peptide of the arginine vasopressin pre-
cursor, is elevated in hemorrhagic and septic
shock. Shock 2007;28:219-26.
25.
Peacock WF, Nowak R, Christenson R,
DiSomma S, Neath SX, Hartmann O, Mueller
C, Ponikowski P, Möckel M, Hogan C, Wu AH,
Richards M, Filippatos GS, Anand I, Ng LL,
Daniels LB, Morgenthaler N, Anker SD, Maisel
AS. Short-term mortality risk in emergency
department acute heart failure. Acad Emerg
Med 2011;18:947-58.
26.
Tentzeris I, Jarai R, Farhan S, Perkmann
T, Schwarz MA, Jakl G, Wojta J, Huber K.
Complementary role of copeptin and high-
sensitivity troponin in predicting outcome in
patients with stable chronic heart failure. Eur
J Heart Fail 2011;13:726-33.
